IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$42.39 USD
+0.10 (0.24%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $42.31 -0.08 (-0.19%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
IDEAYA Biosciences, Inc. (IDYA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$57.33 | $69.00 | $46.00 | 35.56% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for IDEAYA Biosciences, Inc. comes to $57.33. The forecasts range from a low of $46.00 to a high of $69.00. The average price target represents an increase of 35.56% from the last closing price of $42.29.
Analyst Price Targets (12)
Broker Rating
IDEAYA Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.08 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.09 a month ago based on 11 recommendations.
Of the 12 recommendations deriving the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 91.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 90.91%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 10 | 10 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.08 | 1.08 | 1.09 | 1.09 | 1.09 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/24/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
7/11/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
7/9/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
7/8/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Not Available | Strong Buy |
5/23/2024 | Capital One Securities | Timothy Chiang | Strong Buy | Strong Buy |
5/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/13/2024 | Goldman Sachs | Corinne Johnson | Strong Buy | Strong Buy |
5/7/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/21/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.08 |
ABR (Last week) | 1.08 |
# of Recs in ABR | 12 |
Average Target Price | $57.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -0.55 |